Drug Profile
Nabilone controlled release - AOP Orphan Pharmaceuticals
Alternative Names: Nabilone FDTLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator AOP Orphan Pharmaceuticals AG
- Developer AOP Orphan Pharmaceuticals AG; Innsbruck Medical University
- Class Antiemetics; Cannabinoids; Non-opioid analgesics; Small molecules
- Mechanism of Action Cannabinoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Parkinson's disease
- Phase II Pain
Most Recent Events
- 04 Mar 2021 Nabilone controlled release is still in phase III trials for Parkinson's disease (Treatment-experienced) in Austria (PO) (EudraCT2017-004253-16)
- 20 Feb 2020 Orthopädisches Spital Speising GmbH and AOP Orphan Pharmaceuticals completes the phase II Cannabinoid-Spinal-Fusion-Study trial for Pain in Austria (PO, Capsule) (EudraCT2015-004227-31)
- 15 Jul 2019 AOP Orphan Pharmaceuticals completes a phase II trial in Parkinson's disease in Austria (EudraCT2017-000192-86)